RET and medullary thyroid gland carcinoma: Consistently with the potential modifier role of RET-G691S in MTC, Vandenbosch et al. observed that this polymorphism is able to enhance RET oncogenicity of mutations affecting RET codon 666, by increasing its penetrance in the clinical onset [18].